HCPLive Podcasts

HCPLive.com
  • 5.0 (4)
  • MEDICINE
  • UPDATED BIWEEKLY

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.

  1. Closing the Gap Between IBD Therapies and Patient Outcomes, With David Rubin, MD

    MAY 6

    Closing the Gap Between IBD Therapies and Patient Outcomes, With David Rubin, MD

    Despite more than 14 approved therapies for Crohn's disease and ulcerative colitis, many patients still aren't reaching remission. At DDW 2026, David Rubin, MD, of the University of Chicago Medicine explains why the problem isn't the drugs — it's how and when we use them. He covers early treatment strategies, treat-to-target monitoring, the induction pitfall, and when to switch mechanisms rather than cycling within class. Read more: https://www.hcplive.com/view/closing-the-gap-between-ibd-therapies-and-patient-outcomes-with-david-rubin-md

    11 min

  2. APR 19

    FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval

    HCPLive Podcasts

    14 min
  3. Liver Lineup: Closing the Gap in Women’s Liver Health

    APR 16

    Liver Lineup: Closing the Gap in Women’s Liver Health

    In this episode of Liver Lineup, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by Meena Bansal, MD, to examine how liver disease uniquely affects women across the lifespan. While conditions like metabolic dysfunction-associated steatotic liver disease (MASLD) are often discussed in broad terms, the trio highlights how risk, progression, and outcomes can differ significantly based on sex and hormonal status.  From reproductive years through menopause and beyond, physiologic changes play a central role in shaping liver health, but these distinctions have historically been underrecognized in both research and clinical care. Key Episode Timestamps 0:00:00 – Welcome & women’s liver health framework0:03:17 – Menopause, estrogen loss, and fibrosis risk0:10:57 – PCOS, young women, and high‑risk metabolic phenotypes0:13:54 – Pregnancy, MASH, and maternal-fetal outcomes0:18:45 – Screening strategy, menopause as a pivot, and intervals0:28:03 – Practical toolkit: FIB‑4, second‑line tests, and who to test0:31:27 – Management, GLP‑1s, resmetirom, and key takeaways https://www.hcplive.com/view/liver-lineup-closing-the-gap-in-women-s-liver-health

    45 min
  4. Liver Lineup: Navigating Genetic Testing in Cholestatic Liver Disease

    APR 7

    Liver Lineup: Navigating Genetic Testing in Cholestatic Liver Disease

    In this episode of Liver Lineup, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by Saul Karpen, MD, PhD, and Robert Gish, MD, for a practical, clinician-focused discussion on the evolving role of genetic testing in cholestatic liver disease. As genetic panels become more widely used in hepatology, many clinicians are left wondering when to order these tests—and how to interpret the results when they come back. From unexplained cholestasis and AMA-negative PBC to intrahepatic cholestasis of pregnancy and atypical liver enzyme patterns, the conversation explores where genetic testing can add real clinical value. Karpen and Gish break down the basics of modern genetic panels, including how they’ve evolved over time, what clinicians should look for in results, and how to approach common challenges like variants of uncertain significance (VUS). The discussion also highlights key genes, such as ABCB4 and ABCB11, and explains how genetic findings can influence diagnosis, risk assessment, and treatment decisions. Read more: https://www.hcplive.com/view/liver-lineup-navigating-genetic-testing-in-cholestatic-liver-disease

    56 min
  5. HCPLive 5 Stories in Under 5: Week of 03/08

    MAR 15

    HCPLive 5 Stories in Under 5: Week of 03/08

    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! RAINIER: Povetacicept Reduces Proteinuria By 52.0%A pre-specified week 36 interim analysis of the phase 3 RAINIER trial found that povetacicept, a dual BAFF/APRIL inhibitor, reduced proteinuria by 52% from baseline and achieved a statistically significant 49.8% reduction in UPCR versus placebo in patients with IgA nephropathy. Lorundrostat Secures FDA NDA Acceptance for Hypertension, Falls Short in Phase 2 OSA TrialThe FDA accepted Mineralys Therapeutics' NDA for lorundrostat as an add-on treatment for hypertension, supported by phase 3 and phase 2 trial data, with a PDUFA action date set for December 22, 2026. Discontinuing GLP-1 Treatment Associated With Up to 60% Weight Regain, With Brajan BudiniNew findings indicate that stopping GLP-1 receptor agonist therapy leads to a predictable pattern of weight regain—reaching approximately 60% at one year before plateauing—suggesting meaningful but substantially diminished long-term benefit after cessation. FDA Approves Leucovorin Calcium (Wellcovorin) Tablets as First Cerebral Folate Deficiency TreatmentThe FDA approved GSK's leucovorin calcium tablets as the first treatment for cerebral folate deficiency in patients with a confirmed FOLR1 gene variant, based on a systematic review of published literature and mechanistic data. New Long-Term Data Announced on Roflumilast Cream for Atopic Dermatitis in ChildrenLong-term data from the INTEGUMENT-OLE extension study show that once-daily roflumilast cream 0.05% is safe and well-tolerated in children aged 2 to 5 with mild-to-moderate atopic dermatitis, with efficacy not only sustained but continuing to improve through 56 weeks of treatment.

    5 min
  6. HCPLive 5 Stories in Under 5: Week of 02/15

    FEB 24

    HCPLive 5 Stories in Under 5: Week of 02/15

    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous NephropathyObinutuzumab demonstrated superior complete remission rates at 2 years compared with tacrolimus in primary membranous nephropathy in the phase 3 MAJESTY trial, supporting a potential new B-cell–targeted standard of care. Ixekizumab, Tirzepatide Effective Together for Psoriasis and Obesity or OverweightIn adults with moderate-to-severe plaque psoriasis and obesity or overweight, combination therapy with ixekizumab and tirzepatide achieved superior skin clearance and weight reduction at 36 weeks compared with ixekizumab alone. AREXVY Vaccine Reduces Hospitalization, Major Adverse Cardiovascular Events in RSVReal-world data from over 2.5 million patients showed GSK’s AREXVY vaccine was 75.6% effective against RSV-related hospitalization, with additional signals suggesting reduced in-hospital major adverse cardiovascular events in older adults. COMP360 Psilocybin Meets Primary Endpoint in Second Phase 3 Trial for TRDCOMP360 synthetic psilocybin met the primary endpoint in its second phase 3 trial in treatment-resistant depression, demonstrating significant symptom reduction at week 6 versus low-dose control and advancing toward potential regulatory submission. Thykamine Shows Disease-Modifying Potential in MASH Using Liver-on-a-Chip PlatformPreclinical data using a human liver-on-a-chip model suggest Thykamine may exert dose-dependent antifibrotic and anti-inflammatory effects in MASH, supporting further translational development.

    6 min
  7. ICD-10 Adoption and the True Burden of Short Bowel Syndrome With Alan Buchman, MD, MSPH

    FEB 18

    ICD-10 Adoption and the True Burden of Short Bowel Syndrome With Alan Buchman, MD, MSPH

    Accurately defining the population of patients with short bowel syndrome (SBS) and intestinal failure has long been a challenge in gastroenterology.  In an effort to bring greater clarity to the field, Alan Buchman MD, MSPH, a professor of Clinical Surgery and Medical Director of the Intestinal Rehabilitation and Transplant Center at the University of Illinois at Chicago and director of gastroenterology at Elevance Health, led the introduction of new, more specific ICD-10-CM codes for SBS, along with corresponding updates to World Health Organization ICD-11 classifications.  His recent real-world US claims analysis presented at the ASPEN 2026 Nutrition Science and Practice Conference examined how widely those codes have been adopted and what that adoption, or lack thereof, reveals about disease burden and clinical practice. Key Interview Time Stamps0:00:00 What prompted this analysis of ICD code adoption in short bowel syndrome?0:01:17 Key findings 0:03:33 Understanding reasons for variability in code adoption0:04:36 The potential benefits of improved coding accuracy

    7 min
  8. When Platelet Increments Matter, With Ruchika Goel, MD

    FEB 13

    When Platelet Increments Matter, With Ruchika Goel, MD

    HCPLive Podcasts

    7 min
See All (236)

Ratings & Reviews

5
out of 5
4 Ratings

About

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.

Information

  • Creator
    HCPLive.com
  • Years Active
    2019 - 2026
  • Episodes
    236
  • Rating
    Clean
  • Show Website
    HCPLive Podcasts